Literature DB >> 2480845

Relative positions of some epitopes on carcinoembryonic antigen.

A Larsson1, R Ghosh, S Hammarström.   

Abstract

To investigate whether anti-(carcinoembryonic antigen) monoclonal antibodies (mAb) react with single or repeated epitopes, sandwich radioimmunoassays in homologous and heterologous combinations were performed. Four mAb (I-27, I-47, II-17 and to some degree II-16) gave homologous binding while two mAb (I-38S1 and II-10) did not. Taken together with previous immunoprecipitation studies we conclude that all these mAb except II-10 react with repeated epitopes. The relative positions of the epitopes recognized by these mAb and of three additional mAb (II-6, II-7 and CB-CEA-1) were investigated using a plate antibody competition test with enzyme-labelled carcinoembryonic antigen (CEA). mAb I-38S1, II-6, II-7, II-10, II-16 and CB-CEA-1 were mutually cross-reactive, and were classified as belonging to one epitope group. mAb I-27 and I-47 fell outside this group and did not interfere with the binding of CEA conjugate to mAb II-17 either. They therefore represent a second epitope group. mAb II-17 showed no interference with the binding of CEA to any of the other mAb and must therefore represent a third epitope group. The slopes of the plate antibody competition curves were used for calculation of a correlation matrix, which in turn was used to depict the relative positions of the epitopes recognized by the mAb in the large group.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2480845     DOI: 10.1007/bf01665959

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

1.  Epitope specificity and cross-reactivity pattern of a large series of monoclonal antibodies to carcinoembryonic antigen.

Authors:  A Hedin; F Zoubir; T Lundgren; S Hammarström
Journal:  Mol Immunol       Date:  1986-10       Impact factor: 4.407

Review 2.  CEA-related antigens: molecular biology and clinical significance.

Authors:  J E Shively; J D Beatty
Journal:  Crit Rev Oncol Hematol       Date:  1985       Impact factor: 6.312

3.  Specificities and binding properties of eight monoclonal antibodies against carcinoembryonic antigen.

Authors:  A Hedin; S Hammarström; A Larsson
Journal:  Mol Immunol       Date:  1982-12       Impact factor: 4.407

4.  A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum.

Authors:  M A Markwell
Journal:  Anal Biochem       Date:  1982-09-15       Impact factor: 3.365

5.  Determination of intrinsic affinity constants of monoclonal antibodies against carcinoembryonic antigen.

Authors:  A Larsson; R Ghosh; S Hammarström
Journal:  Mol Immunol       Date:  1987-06       Impact factor: 4.407

6.  Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen.

Authors:  N Beauchemin; S Benchimol; D Cournoyer; A Fuks; C P Stanners
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

7.  Use of limitations of radiolabeled anti-CEA antibodies and their fragments for photoscanning detection of human colorectal carcinomas.

Authors:  J P Mach; M Forni; J Ritschard; F Buchegger; S Carrel; S Widgren; A Donath; P Alberto
Journal:  Oncodev Biol Med       Date:  1980-08

8.  Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence.

Authors:  S Oikawa; H Nakazato; G Kosaki
Journal:  Biochem Biophys Res Commun       Date:  1987-01-30       Impact factor: 3.575

9.  Colorectal tumors: scintigraphy with In-111 anti-CEA monoclonal antibody and correlation with surgical, histopathologic, and immunohistochemical findings.

Authors:  H H Abdel-Nabi; A N Schwartz; G Goldfogel; J A Ortman-Nabi; D M Matsuoka; M W Unger; D G Wechter
Journal:  Radiology       Date:  1988-03       Impact factor: 11.105

10.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

Authors:  P GOLD; S O FREEDMAN
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.